PURPOSE: Hyperpolarized 13 C MRI is a powerful tool for studying metabolism, but can lack tissue specificity. Gadoxetate is a gadolinium-based MRI contrast agent that is selectively taken into hepatocytes. The goal of this project was to investigate whether gadoxetate can be used to selectively suppress the hyperpolarized signal arising from hepatocytes, which could in future studies be applied to generate specificity for signal from abnormal cell types. METHODS: Baseline gadoxetate uptake kinetics were measured using T1 -weighted contrast enhanced imaging. Relaxivity of gadoxetate was measured for [1-13 C]pyruvate, [1-13 C]lactate, and [1-13 C]alanine. Four healthy rats were imaged with hyperpolarized [1-13 C]pyruvate using a three-dimensional (3D) MRSI sequence prior to and 15 min following administration of gadoxetate. The lactate:pyruvate ratio and alanine:pyruvate ratios were measured in liver and kidney. RESULTS: Overall, the hyperpolarized signal decreased approximately 60% as a result of pre-injection of gadoxetate. In liver, the lactate:pyruvate and alanine:pyruvate ratios decreased 42% and 78%, respectively (P < 0.05) following gadoxetate administration. In kidneys, these ratios did not change significantly. Relaxivity of gadoxetate for [1-13 C]alanine was 12.6 times higher than relaxivity of gadoxetate for [1-13 C]pyruvate, explaining the greater selective relaxation effect on alanine. CONCLUSIONS: The liver-specific gadolinium contrast-agent gadoxetate can selectively suppress normal hepatocyte contributions to hyperpolarized 13 C MRI signals. Magn Reson Med 77:2356-2363, 2017.
PURPOSE: Hyperpolarized 13 C MRI is a powerful tool for studying metabolism, but can lack tissue specificity. Gadoxetate is a gadolinium-based MRI contrast agent that is selectively taken into hepatocytes. The goal of this project was to investigate whether gadoxetate can be used to selectively suppress the hyperpolarized signal arising from hepatocytes, which could in future studies be applied to generate specificity for signal from abnormal cell types. METHODS: Baseline gadoxetate uptake kinetics were measured using T1 -weighted contrast enhanced imaging. Relaxivity of gadoxetate was measured for [1-13 C]pyruvate, [1-13 C]lactate, and [1-13 C]alanine. Four healthy rats were imaged with hyperpolarized [1-13 C]pyruvate using a three-dimensional (3D) MRSI sequence prior to and 15 min following administration of gadoxetate. The lactate:pyruvate ratio and alanine:pyruvate ratios were measured in liver and kidney. RESULTS: Overall, the hyperpolarized signal decreased approximately 60% as a result of pre-injection of gadoxetate. In liver, the lactate:pyruvate and alanine:pyruvate ratios decreased 42% and 78%, respectively (P < 0.05) following gadoxetate administration. In kidneys, these ratios did not change significantly. Relaxivity of gadoxetate for [1-13 C]alanine was 12.6 times higher than relaxivity of gadoxetate for [1-13 C]pyruvate, explaining the greater selective relaxation effect on alanine. CONCLUSIONS: The liver-specific gadolinium contrast-agent gadoxetate can selectively suppress normal hepatocyte contributions to hyperpolarized 13 C MRI signals. Magn Reson Med 77:2356-2363, 2017.
Authors: Mustafa R Bashir; Steven R Breault; Ryan Braun; Richard K Do; Rendon C Nelson; Scott B Reeder Journal: Acad Radiol Date: 2014-04-06 Impact factor: 3.173
Authors: Simon Hu; Minhua Zhu; Hikari A I Yoshihara; David M Wilson; Kayvan R Keshari; Peter Shin; Galen Reed; Cornelius von Morze; Robert Bok; Peder E Z Larson; John Kurhanewicz; Daniel B Vigneron Journal: Magn Reson Imaging Date: 2011-08-19 Impact factor: 2.546
Authors: Matthew R Smith; Eric T Peterson; Jeremy W Gordon; David J Niles; Ian J Rowland; Krishna N Kurpad; Sean B Fain Journal: IEEE Trans Biomed Eng Date: 2011-07-18 Impact factor: 4.538
Authors: Charles H Cunningham; Albert P Chen; Mark J Albers; John Kurhanewicz; Ralph E Hurd; Yi-Fen Yen; John M Pauly; Sarah J Nelson; Daniel B Vigneron Journal: J Magn Reson Date: 2007-06-02 Impact factor: 2.229
Authors: Zhen J Wang; Michael A Ohliger; Peder E Z Larson; Jeremy W Gordon; Robert A Bok; James Slater; Javier E Villanueva-Meyer; Christopher P Hess; John Kurhanewicz; Daniel B Vigneron Journal: Radiology Date: 2019-03-05 Impact factor: 11.105
Authors: Irene Marco-Rius; Alan J Wright; De-En Hu; Dragana Savic; Jack J Miller; Kerstin N Timm; Damian Tyler; Kevin M Brindle; Arnaud Comment Journal: MAGMA Date: 2020-09-10 Impact factor: 2.310